Vivalis to buy Intercell in European biotech merger
LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in scale and produce a stronger pipeline to better compete in the quest for lucrative partnership deals. Vivalis is set to buy Intercell in a deal valuing the Austrian vaccine maker at around 133 million euros ($174 million), and creating an enlarged anti-infectives specialist in the fragmented European biotech industry. ...
Source: news.yahoo.com
No comments:
Post a Comment